Clinical Trial Update: 89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma [Phase 1]

View source ↗

Summary

This Phase 1 study evaluates the dosimetry of 89Zr-olaratumab in participants with soft tissue sarcoma. The trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• 89Zr-olaratumab (olaratumab)

Snippet

Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd | Conditions: Soft Tissue Sarcoma | Phase 1 | Status: RECRUITING